2022 American Transplant Congress
Nivolumab After Sorafenib Failure in Liver Recipients with HCC Recurrence
Surgery, Samsung Medical Center, Seoul, Korea, Republic of
*Purpose: Several treatments have recently been known for hepatocellcular carcinoma (HCC) who have failed to treat sorafenib. Immune checkpoint inhibitors have proven to be effective,…2022 American Transplant Congress
Characterizing Outcomes of Patients with Colorectal Liver Metastases (CRLM) Undergoing Liver Transplantation (LT) Evaluation
*Purpose: LT is a novel therapy for patients with unresectable CRLM. 5 year survival using LT appears to be significantly better than systemic chemotherapy in…2022 American Transplant Congress
Frequency of Cervical Cancer Screening in Solid Organ Transplant Recipients
*Purpose: Human papillomavirus-related anogenital malignancies disproportionately affect solid organ transplant recipients (SOTR) compared to the general population. Proposed cervical Pap testing intervals for SOTR differ…2022 American Transplant Congress
Liver Transplantation for Combined Hepatocellular-Cholangiocarcinoma: An Analysis of the European Liver Transplant Registry
*Purpose: Little is known about combined hepatocellular-cholangiocarcinoma (cHCC-CCA) demographics and their long-term outcomes after liver transplantation (LT). By analysing data from the European Liver Transplant…2022 American Transplant Congress
Degree of Pre-Liver Transplant Immune Dysfunction Correlates with Post-Transplant Cancer Recurrence
1Rutgers New Jersey Medical School, Newark, NJ, 2Houston Methodist Hospital, Houston, TX
*Purpose: Despite stringent selection criteria for liver transplant (LT) in patients with liver-limited malignancy, post-transplant cancer recurrence remains problematic. We have previously identified a pre-LT…2022 American Transplant Congress
Use of Targeted T-Cell Therapy (Posoleucel) for the Treatment of Epstein-Barr Virus Associated Leiomyosarcoma in an Adult Kidney Transplant Recipient: A Case Report
*Purpose: Epstein-Barr virus (EBV)-associated leiomyosarcomas (EBV+LMS) are neoplasms rarely seen in solid organ transplant (SOT) recipients and currently lack effective treatment options. We present a…2021 American Transplant Congress
Posttransplant Malignancy in HIV+ Kidney Transplant Recipients
*Purpose: Kidney transplant recipients and people living with HIV are both at increased risk for malignancy, including cancers that are virally-mediated. Despite the recognition of…2021 American Transplant Congress
Associations of Mammalian Target of Rapamycin Inhibitors with Post-Transplant Malignancies and All-Cause Mortality: Cause-Specific Competing Risks and Composite Outcomes Analyses
1University of Florida, Gainesville, FL, 2University of Rhode Island, Kingston, RI
*Purpose: We investigated the outcomes of malignancies and mortality associated with mammalian target of rapamycin inhibitor (MTORI) regimens in adult kidney transplant (KT) recipients (KTRs).*Methods:…2021 American Transplant Congress
Long Term Survival After Liver Transplantation for Advanced, Unresectable Intrahepatic Cholangiocarcinoma
1Houston Methodist Hospital, Houston, TX, 2MD Anderson Cancer Center, Houston, TX
*Purpose: Intrahepatic cholangiocarcinoma (ICCA) has traditionally been considered a contraindication to liver transplantation (LT). We previously reported a case series of six patients with large,…2021 American Transplant Congress
Treg Lymphotoxin Engages Lymphotoxin Receptor on Cancer and Endothelial Cells to Promote Cancer Metastatic Migration: Mechanisms for Treg-Cancer Interactions
*Purpose: Treg immune suppression which is critical for transplant graft survival may also enhance tumor growth and metastases. Treg lymphotoxin (LTα1β2) may directly engage the…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 20
- Next Page »